Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KMDA
STRONG BUYAPPROVEKamada Ltd. · Healthcare · Israel · $410M · Avg Vol: $373K/d
Kamada is a highly specialized biopharmaceutical company with an FDA-approved, state-of-the-art plasma fractionation facility. It acts as a niche CDMO and proprietary producer of life-saving therapeutics. Because plasma-derived products have immense regulatory moats, high switching costs, and inelastic demand, Kamada possesses incredible pricing power. The current geopolitical discount on Israeli assets provides a highly asymmetric entry point for a business with highly resilient global cash flows.
COMPANY DESCRIPTION
Kamada Ltd. is an Israeli biopharmaceutical company specializing in the development, manufacture, and commercialization of plasma-derived protein therapeutics for rare diseases and serious conditions. The company's competitive moat stems from its expertise in plasma protein purification and its vertically integrated operations, which encompass plasma collection to commercialization of its specialized orphan drug portfolio for niche patient populations.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 129.3M | 142.5M | 161.0M | 180.5M | 11.7% |
| EPS | — | -0.05 | 0.17 | 0.25 | 0.35 | 43.5% |
| Shares | — | 44.8M | 57.5M | 57.5M | 57.7M | +28.7% |
| Debt | 17.4M | 20.6M | 8.8M | 11.1M | 11.6M | -9.7% |
| Equity | — | 176.0M | 244.0M | 259.5M | 269.1M | 15.2% |
| Op CF | — | 28.6M | 4.3M | 47.6M | 25.5M | -3.7% |
| Inv CF | — | -3.8M | -5.8M | -10.7M | -9.8M | — |
| Fin CF | — | -9.3M | 22.7M | -13.9M | -18.3M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KMDA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KMDA | Kamada Ltd.(you) | $410M | 95 | STRONG BUY |
| INMD | InMode Ltd. | $763M | 98 | STRONG BUY |
| CGEN | Compugen Ltd. | $196M | 93 | STRONG BUY |
| BWAY | BrainsWay Ltd. | $585M | 83 | STRONG BUY |
| TEVAN.MX | Teva Pharmaceutical Industries Limited | $36.7B | 33 | SELL |
| 1696.HK | Sisram Medical Ltd | $134M | 64 | HOLD |
| SLGL | Sol-Gel Technologies Ltd. | $246M | 39 | HOLD |
| DRTS | Alpha Tau Medical Ltd. | $890M | 36 | HOLD |
| BVC.L | BATM Advanced Communications Ltd. | $69M | 56 | HOLD |
| ENLV | Enlivex Ltd. | $146M | 18 | STRONG SELL |
Peer medians: ROE 1.1% · P/E 8.9x · Gross margin 20.9%